The new EU compass could support small companies to grow their market share across Europe, assisted by fewer regulatory ...

as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly. Mazdutide – a once-weekly injectable Innovent licensed from Lilly – was submitted to China's ...

Other GLP-1-targeting drugs for obesity and diabetes are also being explored for their potential in MASH – including Novo Nordisk’s Ozempic/Wegovy (semaglutide) and Eli Lilly’s Mounjaro ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline. Click for my LLY stock update.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...